FDA Approves New Oral Option for Plaque Psoriasis

Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.

1

The FDA approved icotrokinra, an oral interleukin-23 receptor antagonist, for moderate-to-severe plaque psoriasis in patients aged 12 and older.
2

Icotrokinra offers a new oral treatment option, potentially replacing injectable biologics for patients not responding to topical therapies.
3

In clinical trials, approximately 70% of patients achieved clear or nearly clear skin, with 55% showing a 90% reduction in disease severity by week 16.
4

Adverse events were similar to placebo, with common side effects including headache, nausea, cough, fatigue, and fungal infection.
5

Plaque psoriasis affects over 8 million people in the US, impacting their physical comfort and quality of life, especially in sensitive areas.

1